Global Bronchodilators Market Size study & Forecast, by Indication (Asthma, Chronic obstructive pulmonary disease (COPD), Others), by Drug Type (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), by Route Of Administratio

Global Bronchodilators Market Size study & Forecast, by Indication (Asthma, Chronic obstructive pulmonary disease (COPD), Others), by Drug Type (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), by Route Of Administration (Oral, Injection, Inhaler) and Regional Analysis, 2022-2029

Global Bronchodilators Market is valued at approximately USD 33.78 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.2% over the forecast period 2022-2029. A bronchodilator is a type of drug that relaxes the muscles in the lungs (bronchi) airway passageways and widens them to make breathing easier. They enhance airflow within the lungs and lessen resistance in the respiratory tract. Additionally, bronchodilators are utilized to lessen pulmonary mucus. These medications are taken by patients with respiratory conditions using inhalers or nebulizers. Inhalation bronchodilators additionally influence mucociliary clearance. By relaxing the muscles in the lungs and enlarging the airways, bronchodilators are employed in the treatment of obstructive lung disorders (bronchi). The growing awareness regarding the treatment of lung diseases, increasing geriatric population, coupled with the rise in number of smokers are the primary factors that are fostering the market demand across the globe.

The rising prevalence of lung diseases is acting as a chief driving factor for the growth of the global market. For instance, the World Health Organization (WHO) lists respiratory disease infections as the third leading cause of mortality, accounting for around 3 million deaths per year (or 6% of all fatalities worldwide), with nearly 90% of COPD fatalities occurring in individuals over 70 from low- and middle-income nations. Also, it is estimated that 262 million people worldwide have asthma, which typically affects youngsters. Thus, the high incidences of various respiratory and lung diseases are augmenting the market demand at a substantial rate. Moreover, the heightened pollution levels globally, as well as the growing R&D investments related to bronchodilators are presenting various lucrative opportunities over the forecasting years. However, the adverse effects of bronchodilators and long approval times and stringent regulations are hindering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bronchodilators Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness regarding the treatment of COPD, asthma, and other chronic respiratory disorders, along with the rising number of government initiatives. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as the high presence of respiratory disorder patient pool, improving healthcare infrastructure, and rise in demand for bronchodilators in the pharmaceutical sector across the regional market.

Major market players included in this report are:
Abbott Laboratories
AstraZeneca plc.
Boehringer Ingelheim International GmbH
GlaxoSmithKline Plc.
F. Hoffmann-La Roche Ltd.
Novartis AG.
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries Ltd.
Vectura Group Plc

Recent Developments in the Market:
In May 2020, Glenmark Pharmaceuticals Ltd. declared that the company has successfully launched its Single Inhaler Triple Therapy (AIRZ-FF) which is a combination of two bronchodilators, namely, Formoterol and Glycopyrronium, and corticosteroid Fluticasone propionate. The product is specially designed for Chronic Obstructive Pulmonary Disease (COPD) patients in India.
In October 2020, Zydus Cadila announced that the company received final approval from the United States Food and Drug Administration (USFDA) to trade its Albuterol Tablets (in the strengths of 2 mg and 4 mg) which are used to treat and prevent bronchospasm.

Global Bronchodilators Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Indication, Drug Type, Route Of Administration, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Indication:
Asthma
Chronic obstructive pulmonary disease (COPD)
Others

By Drug Type:
Sympathomimetics
Anticholinergics
Phosphodiesterase Inhibitor
Combination Drugs
By Route Of Administration:
Oral
Injection
Inhaler

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Abbott Laboratories
AstraZeneca plc.
Boehringer Ingelheim International GmbH
GlaxoSmithKline Plc.
F. Hoffmann-La Roche Ltd.
Novartis AG.
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries Ltd.
Vectura Group Plc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.